Gefitinib attenuates murine pulmonary fibrosis induced by bleomycin

Chinese Medical Journal

Volumn 123, Issue 16, 2010, Pages 2259-2264

  Wang, Ping ^a   Tian, Qing ^a   Liang, Zhi Xin ^a   Yang, Zhen ^a   Xu, Shu Feng ^b   Sun, Ji Ping ^a   Chen, Liang An ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b FIRST HOSPITAL OF QINHUANGDAO   (China)

Author keywords

Epidermal growth factor; Fibroblasts; Gefitinib; Idiopathic pulmonary fibrosis; Tyrosine kinase inhibitor

Indexed keywords

BLEOMYCIN; CALVASCULIN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; LUNG FIBROBLAST; LUNG FIBROSIS; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; BLEOMYCIN; BLOTTING, WESTERN; COLLAGEN TYPE I; COLLAGEN TYPE III; MALE; MICE; MICE, INBRED C57BL; PROTEIN KINASE INHIBITORS; PULMONARY FIBROSIS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 77956127160     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2010.16.019     Document Type: Article

References (29)

1. Van Zoelen EJ, Stortelers C, Lenferink AE, Van de Poll ML. The EGF domain: requirements for binding to receptors of the ErbB family. Vitam Horm 2000; 59: 99-131.
2. Schneider MR, Werner S, Paus R, Wolf E. Beyond wavy hairs: The epidermal growth factor receptor and its ligands in skin biology and pathology. Am J Pathol 2008; 173: 14-24.
3. Mitsudomi T, Yatabe Y. Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. FEBS J 2010; 277: 301-308.
4. Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008; 372: 1809-1818.
5. Wang MZ, Li LY, Wang SL, Zhang XT, Zhong W, Zhang L. Efficacy and safety of gefitinib as monotherapy for Chinese patients with advanced non-small cell lung cancer. Chin Med J 2006; 119: 63-68.
6. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003; 21: 2237-2246.
7. Thatcher N, Chang A, Parikh P, Pereira JR, Ciuleanu T, von Pawel J, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366: 1527-1537.
8. Kaneda H, Tamura K, Kurata T, Uejima H, Nakagawa K, Fukuoka M. Retrospective analysis of the predictive factors associated with the response and survival benefit of gefitinib in patients with advanced non-small-cell lung cancer. Lung Cancer 2004; 46: 247-254.
9. Inoue A, Saijo Y, Maemondo M, Gomi K, Tokue Y, Ebina M, et al. Severe acute interstitial pneumonia and gefitinib. Lancet 2003; 361: 137-139.
10. Gross TJ, Hunninghake GW. Idiopathic pulmonary fibrosis. N Engl J Med 2001; 345: 517-525.
11. Wang ZL. Advances in understanding of idiopathic pulmonary fibrosis. Chin Med J 2009; 122: 844-857.
12. Du Bois RM, Wells AU. Cryptogenic fibrosing alveolitis/idiopathic pulmonary fibrosis. Eur Respir J Suppl 2001; 32: 43s-55s.
13. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000; 161: 646-664.
14. Collard HR, King TE. Demystifying idiopathic interstitial pneumonia. Arch Intern Med 2003; 163: 17-29.
15. Zavadil J, Böttinger EP. TGF-beta and epithelial-tomesenchymal transitions. Oncogene 2005; 24: 5764-5774.
16. Hay ED. An overview of epithelio-mesenchymal transformation. Acta Anat 1995; 154: 8-20.
17. Thiery JP. Epithelial-mesenchymal transitions in tumor progression. Nat Rev Cancer 2002; 2: 442-454.
18. Iwano M, Plieth D, Danoff TM, Xue C, Okada H, Neilson EG. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest 2002; 110: 341-350.
19. Saika S, Kono-Saika S, Ohnishi Y, Sato M, Muragaki Y, Ooshima A, et al. Smad3 signaling is required for epithelial-mesenchymal transition of lens epithelium after injury. Am J Pathol 2004; 164: 651-663.
20. Adamson IYR, Bowden DH. Type 2 cell as progenitor of alveolar epithelial regeneration: a cytodynamic study in mice after exposure to oxygen. Lab Invest 1974; 30: 35-42.
21. Grünert S, Jechlinger M, Beug H. Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. Nat Rev Mol Cell Boil 2003; 4: 657-665.
22. Kasai H, Allen JT, Mason RM, Kamimura T, Zhang Z. TGF-beta1 induces human alveolar epithelial to mesenchymal cell transition (EMT). Respir Res 2005; 6: 56.
23. Baughman RP, Lower EE, Miller MA, Bejarano PA, Heffelfinger SC. Overexpression of transforming growth factor alpha and epidermal growth factor-receptor in idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16: 57-61.
24. Madtes DK, Busby HK, Strandjord TP, Clark JG. Expression of transforming growth factor-alpha and epidermal growth factor receptor is increased following bleomycin-induced lung injury in rats. Am J Respir Cell Mol Biol 1994; 11: 540-551.
25. Ashcroft T, Simpson JM, Timbrell V. Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J Clin Pathol 1998; 41: 467-470.
26. Rice AB, Moomaw CR, Morgan DL, Bonner JC. Specific inhibitors of platelet-derived growth factor or epidermal growth factor receptor tyrosine kinase reduce pulmonary fibrosis in rats. Am J Pathol 1999; 155: 213-221.
27. Ishii Y, Fujimoto S, Fukuda T. Gefitinib prevents bleomycin-induced lung fibrosis in mice. Am J Respir Crit Care Med 2006; 174: 550-556.
28. Wang C, Abe S, Matsuda K, Yu C, Li Y, Usuki J, et al. Effects of gefitinib on radiation-induced lung injury in mice. J Nippon Med Sch 2008; 75: 96-105.
29. Suzuki H, Aoshiba K, Yokohori N, Nagai A. Epidermal growth factor receptor tyrosine kinase inhibition augments a murine model of pulmonary fibrosis. Cancer Res 2003; 63: 5054-5059.